Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Pankovich

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancers|January 8, 2023
Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100Brian J Park, Paromita Raha, Jim Pankovich, et al.
AIDS Patient Care and Stds|May 9, 2013
Gender disparities in HIV risk behavior and access to health care in St. Petersburg, RussiaColins Vasquez, Dmitry Lioznov, Svetlana Nikolaenko, et al.
Biomolecules|July 29, 2023
The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral ActivityDaniel S Labach, Hinissan P Kohio, Edwin A Tse, et al.
Open Forum Infectious Diseases|October 30, 2015
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir ReductionMario Ostrowski, Erika Benko, Feng Yun Yue, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in CanadaStephen Sundquist, Gerald Batist, Kathy Brodeur-Robb, et al.
Molecular Cancer Research : MCR|July 31, 2024
Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis ModulationDaryl Griffin, Robbie Carson, Debbie Moss, et al.
Oncoimmunology|February 6, 2018
Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapyMark Bazett, Amanda M Costa, Momir Bosiljcic, et al.
Frontiers in Immunology|October 16, 2018
Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative ColitisHo Pan Sham, Mark Bazett, Momir Bosiljcic, et al.
Frontiers in Medicine|August 6, 2019
Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseSimon Sutcliffe, Shirin Kalyan, Jim Pankovich, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancers|January 8, 2023
Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100Brian J Park, Paromita Raha, Jim Pankovich, et al.
AIDS Patient Care and Stds|May 9, 2013
Gender disparities in HIV risk behavior and access to health care in St. Petersburg, RussiaColins Vasquez, Dmitry Lioznov, Svetlana Nikolaenko, et al.
Biomolecules|July 29, 2023
The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral ActivityDaniel S Labach, Hinissan P Kohio, Edwin A Tse, et al.
Open Forum Infectious Diseases|October 30, 2015
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir ReductionMario Ostrowski, Erika Benko, Feng Yun Yue, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in CanadaStephen Sundquist, Gerald Batist, Kathy Brodeur-Robb, et al.
Molecular Cancer Research : MCR|July 31, 2024
Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis ModulationDaryl Griffin, Robbie Carson, Debbie Moss, et al.
Oncoimmunology|February 6, 2018
Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapyMark Bazett, Amanda M Costa, Momir Bosiljcic, et al.
Frontiers in Immunology|October 16, 2018
Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative ColitisHo Pan Sham, Mark Bazett, Momir Bosiljcic, et al.
Frontiers in Medicine|August 6, 2019
Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseSimon Sutcliffe, Shirin Kalyan, Jim Pankovich, et al.
Pageof 1